ABL Bio said March 5 it will attend the 5th East-West Biopharma Summit: Seoul, set for March 9-11. The event is co-hosted by global biotech publication BioCentury and biopharma executive network BayHelix, with McKinsey & Company participating as an insights partner.
The summit brings together pharmaceutical and biotech industry officials to share insights on global markets and explore new business opportunities. Companies expected to attend include Eli Lilly, Roche, Boehringer Ingelheim, Merck (MSD) and GlaxoSmithKline (GSK).
ABL Bio CEO Lee Sang-hoon is scheduled to join the “Deal Maker Showcase” session on March 10 as a panelist. He plans to discuss key strategies for successful technology-transfer deals with global companies, along with lessons learned from negotiations, including missteps. The company said it also plans business development talks with global firms and will seek partnership opportunities.
Dongkook Pharmaceutical said March 5 it will release a new “mela-proof” ampoule under its dermacosmetic brand Centellian24, called the “Expert Madeca Mela Capture Toning Shot Ampoule.”
The company said the product is the latest version of its “Expert Madeca Mela Capture Ampoule,” which has sold more than 21 million units cumulatively since its 2019 launch.
The new product applies a “mela-proof” solution designed to manage multiple factors that accelerate melanin production. The company said it showed results indicating skin temperature dropped by about 6.68 degrees Celsius immediately after use, and it was designed to address melanin concerns linked to ultraviolet exposure and skin heat.
Dongkook said it combined its key ingredient, a standardized extract of Centella asiatica (TECA), with its patented melanin-related ingredient “MELA-WHITE,” and applied a three-step ultra-low-temperature cooling method, “Mela Freeze,” that goes down to minus 120 degrees Celsius. The company said the resulting proprietary ingredient, “SNOW-TECA,” is included at 20,000 ppm.
Medytox said March 5 it carried out employee promotions for 2026.
In the reshuffle, Kim Hak-woo was promoted from director to managing director. The company said Kim earned a master’s degree from Yonsei University and has worked at Medytox for 25 years, overseeing operations at the Osong Plant 3 and the Ochang Plant 1.
Kim Min-ju, a department head at affiliate Newmeco, was also promoted to director. Medytox Group said a total of 114 employees were promoted across research, production, sales, clinical, regulatory affairs and management functions for strong performance.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.